Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2011-03-02 Investor Presentation
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Company Update
Investor Presentation Classification · 98% confidence The document is a detailed presentation, indicated by the structure, slide numbers (Page 7, Page 8), extensive use of bullet points, charts, and forward-looking statements typical of investor briefings. It covers the company's pipeline (MOR103, MOR208, MOR202), partnered programs, technology platforms, and financial results for FY2010 with guidance for 2011. This format strongly suggests an Investor Presentation (IP) or potentially materials related to an Annual General Meeting (AGM-R) or an Earnings Release (ER). However, the depth of pipeline detail, technology review, and financial segment breakdown aligns best with a formal Investor Presentation designed to communicate strategy and performance to the investment community, rather than just an earnings highlight (ER) or a meeting handout (AGM-R). Since it is a comprehensive presentation deck, 'IP' is the most appropriate classification.
2011-03-02 English
Jahresergebnis 2010 & Ausblick 2011
Investor Presentation Classification · 100% confidence The document is a presentation titled 'Jahresergebnis 2010 & Ausblick 2011' (Annual Results 2010 & Outlook 2011). It contains detailed financial tables, segment results, balance sheet data, and strategic outlook information typical of an investor presentation. It is structured as a slide deck with sections on pipeline, technology, and financial performance, which aligns perfectly with the definition of an Investor Presentation (IP). FY 2010
2011-03-01 German
Unternehmenspräsentation - J.P. Morgan Healthcare Conference
Investor Presentation Classification · 98% confidence The document text explicitly states it is a presentation given at the "29th Annual J.P. Morgan Healthcare Conference – January 2011". This context strongly indicates that the document is a presentation intended for investors, likely detailing company strategy, pipeline, and technology (Slonomics acquisition). This aligns perfectly with the definition of an Investor Presentation (IP). Although it mentions the company's Annual Report, the primary nature of the document is the conference presentation itself. The length (42,575 chars) is substantial, ruling out a simple Report Publication Announcement (RPA).
2011-01-12 English
Presentation of R&D Day, London
Investor Presentation Classification · 95% confidence The document text is titled 'R&D Day 2010' and contains a detailed agenda with time slots, presentation topics (e.g., 'Simmomonorey', 'Q&A'), and presenter names/titles. This structure is characteristic of a formal presentation event, specifically a Research & Development Day, which is designed to inform investors and stakeholders about strategy and pipeline. This aligns best with the 'Investor Presentation' (IP) category, as it is a structured presentation delivered to an investor audience, even if the focus is R&D rather than general financials. It is not a regulatory filing (like 10-K or ER), nor is it a transcript of a call (CT), but rather the material for a scheduled event.
2010-11-25 English
Präsentation des R&D Day, London
Regulatory Filings Classification · 99% confidence The document text explicitly mentions 'R&D Day 2010' and contains an 'Agenda' with time slots and topics, followed by a list of 'Presenters'. The content structure strongly suggests a presentation or materials prepared for an investor or research and development event, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it is a presentation designed to convey information to investors/analysts about strategy and R&D progress, the most appropriate classification is Investor Presentation (IP). The presence of a 'Safe Harbour' statement further supports this being an investor-facing presentation.
2010-11-25 German
Q3 Bericht 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Zwischenbericht' (Interim Report) for the period January to September 2010 for MorphoSys. It contains detailed financial statements (Income Statement, Balance Sheet, Cash Flow, etc.), management discussion and analysis (Konzern-Zwischenlagebericht), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2010
2010-10-29 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.